The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Therapeutic goals in Waldenström’s macroglobulinemia: achieving disease control
Anna Maria Frustaci, MD, Niguarda Hospital, Milan, Italy, discusses therapeutic goals in Waldenström’s macroglobulinemia. Dr Frustaci notes that the primary goal is to manage the disease, and is hopeful that combination strategies will be adopted in the future. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, you know, first of all, it depends on the strategy that you’re using. You know, of course, if more deep is the response that you achieve, then hopefully better, at the longest are the results. But I would say that in Waldenström’s is typically a chronic disease, so your first goal should be to control the disease. I was saying before, it depends on the treatment...
Yeah, you know, first of all, it depends on the strategy that you’re using. You know, of course, if more deep is the response that you achieve, then hopefully better, at the longest are the results. But I would say that in Waldenström’s is typically a chronic disease, so your first goal should be to control the disease. I was saying before, it depends on the treatment. So with covalent BTK inhibitor, your aim is really to control this disease and maintain it for sure is not to achieve an MRD negativity. I would say that it’s too early for Waldenström’s. In the future, hopefully we will have also a combined strategy. So using different mechanisms of action. And at that point, probably we also will talk about deep remission, MRD, but it’s too early for Waldenström’s. In this moment, we just needed to control the disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Beigene, Janssen, Abbvie, AstraZeneca.
